Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies
Medical marijuana generated more than $4.2 billion in revenue in the U.S. in 2015, according to ArcView Market Research. And they forecast it will surpass $22 billion by 2020, as regulations continue to loosen and patient access increases.
So why is GW Pharmaceuticals Plc (NASDAQ: GWPH), the largest pharma company with a relatively modest market capitalization of $2 billion, developing marijuana-based drugs? Where are Pfizer (NYSE: PFE), Novartis (NYSE: NVS), Merck (NYSE: MRK), Sanofi (NYSE: SNY) and the rest of their Big Pharma brethren? If there’s a “pot” of gold at the end of the rainbow, you can be certain they’ll be in the mix at some point, most likely via the acquisition route.
In fact, ArcView predicts that “Once the behemoth multinational corporations enter the market, they will likely go on an acquisition spree versus directly competing against companies that...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin